Working Group 2
Pharmacogenetic Guideline Development and Optimization
wORKING GROUP 2
Pharmacogenetic Guideline Development and Optimization
Working Group 2 is dedicated to developing and optimizing pharmacogenomic guidelines for cardiovascular therapies. The group identifies clinical areas where genetic insights can significantly improve treatment outcomes and supports the transition toward personalized medicine.
Dr. Amela Jusić
Quant Biomarkers
amelajusic88@gmail.com
By analyzing existing guidelines, genetic variants, and therapeutic approaches, WG2 works on creating structured, evidence-based recommendations for clinical use. A key focus is patient stratification, ensuring that treatment decisions are tailored based on genetic profiles, clinical conditions, and demographic factors. This working group plays a critical role in translating research into practice, enabling clinicians to apply pharmacogenomic knowledge effectively and consistently across different healthcare systems.
Working Group 2 Tasks
TASK 2.1
Systematically summarizing the conditions in cardiovascular medicine
TASK 2.2
PGx guidelines and actionable variants in current use
TASK 2.3
Patient stratification
TASK 2.4
Knowledge transfer